Savara appoints two board members
This article was originally published in Scrip
Savara Pharmaceuticals, a company developing a dry powder antibiotic for MRSA, has appointed two members to its board: Dr Joseph S McCracken and Yuri Pikover. Dr McCracken most recently served as global head of business development & licensing at Roche. Mr Pikover is managing director of 37 Technology Ventures, a boutique venture fund focused on growing start-ups.